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Primary sclerosing cholangitis (PSC) is a severe liver disease of unknown etiology leading
to fibrotic destruction of the bile ducts and ultimately the need for liver transplantation1-3.
We compared 3,789 European ancestry PSC cases to 25,079 population controls across
130,422 single-nucleotide polymorphisms (SNPs) genotyped using Immunochip4. We
identified 12 genome-wide significant associations outside the human leukocyte antigen
(HLA) complex, nine of which were novel, thereby increasing the number of known PSC
risk loci to 16. Despite comorbidity with inflammatory bowel disease (IBD) in 72% of the
patients, six of the 12 loci showed significantly stronger association with PSC than IBD,
suggesting an overlapping yet distinct genetic architecture. We incorporated pleiotropy with
seven diseases clinically co-occurring with PSC and found suggestive evidence for 33
additional PSC risk loci. Together with network analyses, these findings further complete
the genetic risk map of PSC and considerably expand on the relationship between PSC and
other immune-mediated diseases.
The pathogenesis of PSC is poorly understood, and due to lack of effective medical therapy,
PSC remains a leading indication for liver transplantation in Northern Europe and the US5,
despite the relatively low prevalence (1/10,000). Affected individuals are diagnosed at a
median age of 30-40 years and suffer from an increased frequency of IBD (60-80%)5,6 and
autoimmune diseases (25%)7. Conversely, approximately only 5% of patients with IBD
develop PSC5,6. A 9-39-fold sibling relative risk indicates a strong genetic component to
PSC risk8. In addition to multiple strong associations within the HLA complex, recent
association studies have identified genome-wide significant loci at 1p36 (MMEL1/
TNFRSF14), 2q13 (BCL2L11), 2q37 (GPR35), 3p21 (MST1), 10p15 (IL2RA) and 18q21
(TCF4)9-13.
Several theories have been proposed to explain the development of PSC5. The strong HLA
associations and the clinical co-occurrence of immune-mediated diseases suggest that
autoimmunity plays a role. To further characterize the genetic etiology of PSC, we recruited
PSC patients throughout Europe and North America, more than doubling the number of
ascertained cases included in previous genetic studies11. We genotyped 196,524 SNPs in
4,228 PSC cases and 27,077 population controls (see Online Methods and Supplementary
Note) using the Immunochip4,14, a targeted genotyping array with dense marker coverage
across 186 known disease loci from 12 immune-mediated diseases. Outside these 186 loci,
Immunochip also assays thousands of SNPs of intermediate significance from multiple
meta-analyses of immune-mediated diseases.
Following quality control (QC; see Online Methods), 130,422 SNPs from 3,789 PSC cases
and 25,079 population controls were available for analysis (Supplementary Tables 1 and 2,
Supplementary Figures 1 and 2). We imputed a further 80,183 SNPs located in the
Immunochip fine mapping regions using the 1000 Genomes reference panel (Online
Methods). We performed case-control association tests using a linear mixed model as
implemented in MMM15 to minimize the effect of population stratification and sample
relatedness (λGC = 1.02, estimated using 2,544 “null” SNPs, see Online Methods).
We identified twelve non-HLA genome-wide significant (P<5×10−8) susceptibility loci
(Table 1), nine of which were novel (Fig. 1). The most associated SNP within each locus
was a common variant (all risk allele frequencies >0.18) of moderate effect (odds ratios
(ORs) between 1.15 and 1.4) (Table 1). Genotype imputation and stepwise conditional
regressions16 within each locus did not identify additional independent genome-wide
significant signals, nor did genotype-genotype or gender-genotype interaction analyses
(Online Methods).
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For seven of the nine novel loci, the most significantly associated SNP in the locus was the
same SNP or was in strong linkage disequilibrium (LD; r2>0.8) with the original association
reports for another disease (Supplementary Table 3). The two exceptions were 11q23, where
only independent disease associations (r2<0.01) have so far been reported17, and 6q15,
where the most significantly associated PSC variant, rs56258221 (OR=1.23, P=8.36×10−12),
is in low-to-moderate LD with the previously reported BACH2 variants in Crohn’s disease
(r2=0.23) and type 1 diabetes (r2=0.12). Three out of four known non-HLA PSC risk loci
present on the Immunochip passed genotyping QC and were confirmed in our analysis
(1p36, 3p21 and 10p15; see Supplementary Note and Supplementary Fig. 3).
To prioritize candidate genes within the non-HLA genome-wide significant loci, we
searched for functional consequences of the most associated SNPs or SNPs in high LD
(r2>0.8), i.e. missense SNPs (Supplementary Table 4 and Supplementary Fig. 4) and
expression quantitative trait loci (eQTLs) (Supplementary Table 5), and we functionally
annotated risk loci using data from the ENCODE project (Supplementary Table 6 and
Supplementary Note)18. We also constructed networks based on functional similarity
measures (Supplementary Fig. 5 and Online Methods), known protein-protein interactions
(DAPPLE19, Supplementary Table 7 and Supplementary Note), and the published literature
(GRAIL20, Supplementary Fig. 6 and Supplementary Note) to identify important disease-
relevant genes. For six of the 12 genome-wide significant loci, the same gene (MMEL1,
CD28, MST1, SH2B3, CD226 and SIK2) was annotated by more than one method
(Supplementary Table 7), suggesting these as candidates for further investigation at these
loci.
Two newly associated loci are located outside of the Immunochip fine mapping regions
(Figures 1d and 1e). At 11q23, the most strongly associated SNP, rs7937682 (OR=1.17,
P=3.18×10−9), is located in an intron of salt-inducible kinase 2 (SIK2), which both
influences the expression of interleukin-10 in macrophages and Nur77, an important
transcription factor in leukocytes21. The association at 12q13 is with an intronic SNP
(rs11168249, OR=1.15, P=5.49×10−9) within the histone deacetylase 7 (HDAC7) gene,
which has also been associated with IBD22. HDAC7 has been implicated in negative
selection of T cells in the thymus23, a key factor in the development of immune tolerance. A
role for HDAC7 in PSC etiology is supported by the novel association at 19q13, where the
most associated SNP, rs60652743 (OR=1.25, P=6.51×10−10) is located within an intron of
serine-threonine protein kinase D2 (PRKD2). When T cell receptors of thymocytes are
engaged, PRKD2 phosphorylates HDAC7, leading to nuclear exclusion of HDAC7 and loss
of its gene regulatory functions, ultimately resulting in apoptosis and negative selection of
immature T cells24,25. Interestingly, this negative selection takes place due to a loss of
HDAC7-mediated repression of Nur77 (regulated by SIK2)26, linking three novel PSC loci
to this pathway.
The associations at the HLA complex at 6p21 were refined by imputing alleles at HLA-A
HLA-B, HLA-C, HLA-DRB1, HLA-DQB1, HLA-DQA and HLA-DPB1 (see
Supplementary Note)27. The top associated SNP (rs4143332) was in almost perfect LD
(r2=0.996) with HLA-B*08:01 (Supplementary Note). In a stepwise conditional analysis
including both SNP and HLA allele genotypes, rs4143332 (tagging HLA-B*08:01) and a
complex HLA class II association signal determined by HLA-DQA1*01:03 and SNPs
rs532098, rs1794282 and rs9263964 (Supplementary Fig. 7) explain most of the HLA
association signal in PSC.
When performing a stepwise regression of the HLA alleles only, the class II associations are
coherent with previous reports, apart from a novel association with HLA-DQA1*01:01 (see
Supplementary Note and Supplementary Tables 8, 9, 10)9,28,29. The HLA-DRB1*15:01
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association overlaps with that of ulcerative colitis (risk increasing) and Crohn’s disease (risk
decreasing)30,31. Since imputed genotypes at the class II region were only available for four
(HLA-DRB1, HLA-DQB1, HLA-DQA1 and HLA-DPB1) out of 20 loci32, further studies
involving direct sequencing of all HLA class II loci along with assessments of their protein
structure and peptide binding are required to causally resolve the link between this HLA
subregion and PSC development33,34.
Although 72% of the PSC patients in this study have a diagnosis of concomitant IBD
(Supplementary Table 11), only half of our genome-wide significant loci were associated
with IBD in the recent International IBD Genetics Consortium (IIBDGC) Immunochip
analysis (Fig. 2a, Supplementary Table 3 and Supplementary Fig. 8)22, despite the greater
sample size of that study (25,683 cases and 15,977 controls). Across the 12 non-HLA PSC
loci we observed greater similarity between the OR estimates for PSC and ulcerative colitis
than for PSC and Crohn’s disease. We used the Crohn’s disease and ulcerative colitis OR
estimates for the 163 IBD-associated loci to predict PSC case/control status in our sample
(Online Methods)22, and found a significantly greater area under the receiver operating
characteristic curve (AUC) when applying ulcerative colitis ORs compared to Crohn’s
disease ORs (ulcerative colitis AUC=0.62, Crohn’s disease AUC=0.56, P=1.2x10−57, Fig.
2b). This suggests that PSC is genetically more similar to ulcerative colitis than Crohn’s
disease and is consistent with clinical observations of greater comorbidity between PSC with
ulcerative colitis than Crohn’s disease35. To further compare the genetic profile of PSC and
IBD, we combined our genome-wide significant PSC loci with the 163 confirmed IBD
loci22 in a functional similarity network (Supplementary Fig. 9 and Supplementary Table
12). The figure shows that the PSC loci are distributed throughout the IBD loci, suggesting
that there is no particular functional subcluster of IBD susceptibility genes associated with
PSC and vice versa.
While we consider only those loci reaching a stringent significance threshold (P<5×10−8) to
be conclusively associated to PSC, it is likely that additional true associations lie among
SNPs with weaker associations. An alternative approach for controlling for multiple
hypothesis testing is false discovery rate (FDR) control, which regulates the expected
proportion of incorrectly rejected null hypotheses. FDR is well suited to focused genotyping
platforms such as Metabochip36 and Immunochip because it implicitly accounts for the
expected enrichment of association. To further increase this enrichment, we exploited the
known pleiotropy between related immune-mediated traits37, and calculated the FDR38-40
for association with PSC conditional on previously published summary statistics from each
of the related phenotypes (yielding a per SNP conditional FDR)41 (Online Methods). We
identified 33 non-HLA loci with a conditional FDR<0.001 in this analysis (Fig. 3), all of
which showed suggestive significance (5×10−5≤P<5×10−8) in the standard association
analysis (Supplementary Table 13 and Supplementary Figures 10-12). These loci were
integrated in the functional similarity network analysis (Supplementary Fig. 13),
highlighting potential candidate susceptibility genes.
In conclusion, the present study increases the number of genome-wide significant loci in
PSC from seven to 16 (including the HLA complex). The nine novel variants together
explain 0.9% of variance in PSC liability, increasing the total amount of variance explained
by the 16 known loci to 7.3% (Online Methods). The data convincingly show that genetic
susceptibility to PSC extends considerably beyond the risk factors involved in the closely
related IBD phenotype and into autoimmune pathophysiology. Furthermore, analysis of
pleiotropic immune-related genetic variants highlights 33 additional suggestive loci in PSC,
overall representing major new avenues for research into disease pathogenesis.
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Online Methods
Study Subjects
The study participants are described in the Supplementary Note and Supplementary Table
15.
Ethical approval
The patient recruitment was approved by the ethics committees or institutional review
boards of all participating centers. Written informed consent was obtained from all
participants.
Quality control
SNPs with a call rate <80% were removed prior to commencing sample QC (n=235). Per
individual genotype call rate and heterozygosity rate were calculated using PLINK42 and
outlying samples were identified using Aberrant43, which automatically identifies outliers
from otherwise Gaussian distributions (Supplementary Fig. 1). A set of 20,837 LD-pruned
(r2<0.1) SNPs with MAF>10% present on both the Immunochip and the Illumina Omni2.5-8
array used in the 1000 Genomes project (see URLs) were used to estimate identity by
descent and ancestry. For each pair of individuals with estimated identity by descent≥0.9,
the sample with lower call rate was removed (unless case/control status was discordant
between the pair, in which case both samples were removed, n=92). Related individuals
(0.1875<identity by descent<0.9) remained in the analysis to maximize power because the
mixed model association analysis can correctly account for the relatedness. Principal
components analysis, implemented in SMARTPCA (Eigenstrat)44, was used to identify
samples of non-European ancestry. Principal components were defined using population
samples from the 1000 Genomes project45 genotyped using the Illumina Omni2.5-8
genotyping array (see URLs) and then projected into cases and controls (Supplementary Fig.
2)14,22,46. Following sample QC, 3,789 PSC cases and 25,079 controls remained. SNPs with
a minor allele frequency less than 0.1%, Hardy-Weinberg equilibrium P<10−5, call rate
lower than 98%, or failing the PLINK v1.07 non-random differential missing data rate test
between cases and controls (P<10−5) were excluded. After completion of marker QC
(Supplementary Table 2), 131,220 SNPs were available for analysis, further reduced to
130,422 after cluster plot inspection (see below).
Statistical methods
Genomic inflation factor—The Immunochip contains 3,120 SNPs that were part of a
bipolar disease replication effort and other non-immune-related studies. After QC, 2,544 of
these were used as null markers to estimate the overall inflation of the distribution of
association test statistics.
Imputation—Using 85,747 post-QC SNPs located in the Immunochip fine mapping
regions, additional genotypes were imputed using IMPUTE2 with the 1000 Genomes Phase
1 (March, 2012) reference panel of 1,092 individuals47 and 744,740 SNPs. Imputation was
performed separately in ten batches, with the case:control and country of origin ratios
constant across batches. SNPs with a posterior probability less than 0.9 and those with
differential missingness (P<10−5) between the 10 batches were removed, as were SNPs
failing the exclusion thresholds used for genotyped SNP QC. After imputation, a total of
163,379 SNPs in the Immunochip fine mapping regions, including 153,857 SNPs from the
reference panel, were available for analysis.
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Association analysis—Case-control association tests were performed using a linear
mixed model as implemented in MMM15. A covariance matrix, R, of a random effects
component was included in the model to explicitly account for confounding due to
population stratification and cryptic relatedness between individuals. This method has been
shown to better control for population stratification than correction for principal components
or meta-analyses of matched subgroups of cases and controls48-50. R is a symmetric n×n
matrix with each entry representing the relative sharing of alleles between two individuals
compared to the average in the sample, and is typically estimated using genome-wide SNP
data15. To avoid biases in the estimation of R due to the design of the Immunochip, SNPs
were first pruned for LD (r2<0.1). Of the remaining SNPs, we then removed those that lie in
the HLA region or have a minor allele frequency<10%. Finally, we excluded SNPs that
showed modest association (P<0.005) with PSC in a linear regression model fitting the first
10 principal components as covariates. A total of 17,260 SNPs were used to estimate R.
Due to computational limitations, we estimated the R matrix and performed all association
analyses applying R separately for UK (n=9,696) and non-UK (n=19,172) samples, and then
combined the results using a fixed-effects (inverse-variance weighting) meta-analysis, as
done previously48. This reduced the λGC, estimated using the 2,544 “null” SNPS, from 1.24
to 1.02 (Supplementary Fig. 14), showing excellent control for population stratification.
Stepwise conditional regression was used to identify possible independent associations at
genome-wide significant loci. SNP×SNP interactions between all pairs of genome-wide
significant SNPs were tested using the PLINK --epistasis command. Signal intensity plots of
all non-HLA loci with association P-value<5×10−6 were visually inspected using Evoker51.
SNPs that clustered poorly were removed (n=798).
Prediction of PSC using IBD SNPs—ORs for Crohn’s disease and ulcerative colitis in
163 IBD-associated SNPs were obtained from Jostins et al.22. We used the R package
Mangrove (see URLs) to estimate each individual’s probability of developing PSC among
our 3,789 PSC cases and 25,079 controls assuming additive risk (log-additive OR). The
performance of our predictor using either Crohn’s disease or ulcerative colitis ORs, was
assessed by constructing a ROC curve, showing the proportion of true and false positives at
each probability threshold. The AUC was calculated to compare the predictive power of the
ulcerative colitis and Crohn’s disease ORs. The DeLong method was used to test if the AUC
was significantly greater using ulcerative colitis than Crohn’s disease ORs52.
Functional similarity networks—In functional similarity networks, each edge
represents strong functional similarity of two genes based on annotated Gene Ontology
terms as determined by the functional similarity measure rfunSim53. The rfunSim similarity
values above the recommended cutoff 0.8 were retrieved using the FunSimMat web
service54. The resulting networks were visualized and analyzed using Cytoscape55.
To construct PSC-specific networks from functional similarity networks that contained more
than one gene per locus (Supplementary Figures 5 and 13), the connectivity of each gene
was assessed by computing different topology measures for the corresponding node: (1)
degree (number of direct edges to other nodes), (2) shortest path closeness (inverted average
shortest path distance to other nodes) and (3) shortest path betweenness (fraction of shortest
paths passing through the node). Similarity edges between genes in the same locus and gene
nodes that were not contained in the resulting largest connected subnetworks were ignored.
The genes were first ranked according to each measure and then assigned the best of the
three ranks. The PSC-specific network was generated from the top ranked genes in their
respective locus.
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Pleiotropy analysis—We included summary statistics from genome-wide association
studies in seven PSC-associated diseases (Crohn’s disease, celiac disease, psoriasis,
rheumatoid arthritis, sarcoidosis, type 1 diabetes, ulcerative colitis, see Supplementary Table
16). For all diseases we constructed conditional stratified Q-Q plots of empirical quantiles of
nominal −log10(P) values for SNP association with PSC for all SNPs (see Supplementary
Fig. 10), and for different overlapping subsets of SNPs determined by the significance of
their association with the PSC-associated autoimmune disorder (SNP subsets defined as
P<1, P<0.1, P<0.01 and P<0.001 in the pleiotropic phenotype, respectively). For a given
PSC associated phenotype, ‘enrichment’ for pleiotropic signals in PSC can be observed as
an increasing leftward deflection from the expected null line with lower P-value thresholds
in the second phenotype (Supplementary Note). The ‘enrichment’ in the stratified Q-Q
plots is directly interpretable in terms of the true discovery rate (TDR), equivalent to one
minus the FDR56. Specifically, it can be shown that a conservative estimate of FDR can be
calculated from the horizontal shift of the Q-Q curve from the expected line x=y, with a
larger shift corresponding to a smaller FDR for a given nominal P-value (Supplementary
Note). We calculated the conditional TDR as a function of P-value in PSC across a series of
P-value thresholds in the pleiotropic trait (Supplementary Fig. 10).
In order to assess significance of the association with PSC, we assigned a pleiotropic
(conditional) FDR value for PSC per SNP. The pleiotropic FDR value for each SNP is based
on the P-value of the SNP in PSC relative to the P-value distribution of other SNPs in the
same conditioning subset, where subsets are defined by the pleiotropic association (lowest
P-value among associated diseases) of the SNP. Importantly, the conditioning procedure is
blind to the P-value of the SNP with respect to PSC. The pleiotropic FDR is then
interpolated from conditional FDR curves using established stratified FDR methods41,57 (see
Supplementary Note). The increase in power from using pleiotropic FDR is demonstrated
by dividing the total sample in half and observing that empirical replication rates between
the training and test halves increase with decreasing P-value in the pleiotropic disease
(Supplementary Fig. 15). The SNP with lowest FDR within each LD block (as defined by
1000 Genomes) was considered the lead SNP of a new pleiotropic PSC locus, if below a
0.001 threshold (loci defined by FDR<0.001 and FDR<0.01 shown in Supplementary Tables
13 and 14). All test statistics were adjusted for population stratification by genomic control
(see Supplementary Note and Supplementary Fig. 16).
Variance explained and heritability—The proportion of variance explained by the
genome-wide significant loci and HLA alleles was calculated using a liability threshold
model58 assuming a disease prevalence of 10/100,000 and multiplicative risk.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Association results across the nine newly associated primary sclerosing cholangitis
(PSC) loci
Regional association plots of the 9 loci newly associated with PSC at genome-wide
significance (P<5×10−8). Filled-in circles are directly genotyped and hollow triangles are
imputed (see Online Methods) single-nucleotide polymorphisms (SNPs). The color of the
marker (see legend in panel a) illustrates linkage disequilibrium with the most associated
SNP. Since the most associated SNPs in panels d) and e) are located outside Immunochip
fine mapping regions, association results from the discovery panel of the largest PSC
genome-wide association study to date12 are shown as hollow circles and the most
associated SNP is a hollow diamond (genotyped and imputed HapMap release 22 SNPs,
cases overlap with the current study).
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Figure 2. Genetic similarity of primary sclerosing cholangitis (PSC) and inflammatory bowel
disease (IBD) associated loci
a) Comparison of odds ratios (ORs) between the most associated risk allele in PSC and the
same allele in Crohn’s disease and ulcerative colitis across the 12 genome-wide significant
PSC-associated loci. Ulcerative colitis and Crohn’s disease ORs, and the denomination of
IBD loci as ulcerative colitis, Crohn’s disease or both (IBD), were obtained from Jostins et
al.22. The error bars represent 95% confidence intervals around the ORs. *The PSC
associated alleles at 6q15 (BACH2), 10p15 (IL2RA) and 19q13 (PRKD2) are independent
of the reported IBD associations (r2<0.3), but locate to the same broad genetic region; for
this reason these loci are defined as PSC-IBD loci in Supplementary Figure 9, but as PSC
only allelic associations here.
b) Predicting PSC using OR estimates across 163 IBD-associated loci. The green and orange
lines represent the receiver operating characteristic (ROC) curves for discriminating PSC
cases from population controls using ulcerative colitis or Crohn’s disease ORs from 163 loci
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associated with IBD, respectively22. The dashed diagonal line is y=x, and specifies the ROC
curve of a random predictor.
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Figure 3. Pleiotropic primary sclerosing cholangitis (PSC) loci
Manhattan plot of conditional associations in PSC calculated as stratified false discovery
rates (FDRs) based on the results of the present PSC analysis and genetic associations
previously reported in seven immune-mediated diseases (Crohn’s disease, celiac disease,
psoriasis, rheumatoid arthritis, sarcoidosis; type 1 diabetes and ulcerative colitis) (see Online
Methods and Supplementary Figures 10-12). Single-nucleotide polymorphisms (SNPs) in
red represent genome-wide significant findings from the regular association analysis, while
SNPs listed in black are significantly associated with PSC conditional on their pleiotropic
effects across the related immune-mediated diseases. The horizontal red line represents a
threshold of FDR<0.001 (Supplementary Table 13), while the blue line represents a
threshold of FDR<0.01 (see Supplementary Table 14 for full listing).
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m
at
in
; O
R:
 o
dd
s r
at
io
; P
B:
 o
ve
rla
ps
 a
 re
gi
on
 o
f p
ro
te
in
 b
in
di
ng
; R
A
: r
isk
 a
lle
le
; R
A
F:
 ri
sk
 a
lle
le
 fr
eq
ue
nc
y
a S
N
Ps
 fr
om
 n
ov
el
 P
SC
-a
ss
oc
ia
te
d 
lo
ci
 a
re
 sh
ow
n 
in
 b
ol
d.
b L
D
 re
gi
on
s a
ro
un
d 
le
ad
 S
N
Ps
 w
er
e 
ca
lc
ul
at
ed
 b
y 
ex
te
nd
in
g 
in
 b
ot
h 
di
re
ct
io
ns
 a
 d
ist
an
ce
 o
f 0
.1
 c
en
tim
or
ga
ns
 a
s d
ef
in
ed
 b
y 
th
e 
H
ap
M
ap
 re
co
m
bi
na
tio
n 
m
ap
.
c C
an
di
da
te
 g
en
e(s
) w
ith
in 
sam
e L
D 
reg
ion
 as
 th
e a
sso
cia
ted
 SN
Ps
.
d D
en
ot
es
 if
 th
er
e 
ar
e 
SN
Ps
 w
ith
 r2
>
0.
8 
w
ith
 th
e 
hi
t S
N
P 
th
at
 h
av
e 
fu
nc
tio
na
l a
nn
ot
at
io
ns
 (S
up
ple
me
nta
ry 
Ta
ble
s 4
-7)
.
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